Abrocitinib + Placebo
Phase 2Active 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Post-COVID Condition
Conditions
Post-COVID Condition, Fatigue Symptom
Trial Timeline
Dec 27, 2024 → Sep 30, 2026
NCT ID
NCT06597396About Abrocitinib + Placebo
Abrocitinib + Placebo is a phase 2 stage product being developed by Pfizer for Post-COVID Condition. The current trial status is active. This product is registered under clinical trial identifier NCT06597396. Target conditions include Post-COVID Condition, Fatigue Symptom.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06597396 | Phase 2 | Active |
Competing Products
6 competing products in Post-COVID Condition
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Nirmatrelvir/ritonavir + Placebo/ritonavir | Pfizer | Phase 2 | 51 |
| IgPro20 + Placebo | CSL | Phase 3 | 76 |
| Efgartigimod | Argenx | Phase 2 | 49 |
| Vericiguat Oral Tablet | Bayer | Phase 2 | 49 |
| Meplazumab for injection | Pacific Biosciences | Phase 3 | 69 |
| Vortioxetine + Placebo | Brain Biotech | Phase 2 | 44 |